Search research articles
Contact Us
Filters
Showing results (1-10 of 29) with videos related to
Page
of 3
Sort By:
The European Journal of Health Economics : HEPAC : Health Economics in Prevention and Care
|
March 14, 2024
Antivirals to prepare for surges in influenza cases: an economic evaluation of baloxavir marboxil for the Netherlands
Simon van der Pol, Maarten J Postma, Cornelis Boersma
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research
|
March 16, 2017
An Economic Evaluation of Sacubitril/Valsartan for Heart Failure Patients in the Netherlands
Simon van der Pol, Fabian Degener, Maarten J Postma, et al.
Vaccine
|
April 17, 2024
Cost-effectiveness of high-dose influenza vaccination in the Netherlands: Incorporating the impact on both respiratory and cardiovascular hospitalizations
Simon van der Pol, Florian Zeevat, Maarten J Postma, et al.
Bulletin of the World Health Organization
|
June 27, 2024
Performance assessment to improve public health systems
Jochen O Mierau, Simon van der Pol, Amrit Sandhu, et al.
Vaccines
|
April 27, 2026
Potential Public Health and Economic Impact of the Next-Generation COVID-19 Vaccine mRNA-1283 in The Netherlands
Simon van der Pol, Ekkehard Beck, Tjalke Westra, et al.
BMC Health Services Research
|
March 14, 2020
School health in Europe: a review of workforce expenditure across five countries
Simon van der Pol, Maarten J Postma, Danielle E M C Jansen
Antimicrobial Stewardship & Healthcare Epidemiology : ASHE
|
January 30, 2023
Costs of two vancomycin-resistant enterococci outbreaks in an academic hospital
Simon van der Pol, Mariëtte Lokate, Maarten J Postma, et al.
Pharmacoeconomics
|
February 20, 2025
Cost-Effectiveness Analysis of Nirsevimab for Preventing Respiratory Syncytial Virus-Related Lower Respiratory Tract Disease in Dutch Infants: An Analysis Including All-Infant Protection
Florian Zeevat, Simon van der Pol, Alexia Kieffer, et al.
Advances in Therapy
|
February 10, 2025
Cost-effectiveness Analysis of COVID-19 mRNA XBB.1.5 Fall 2023 Vaccination in the Netherlands
Florian Zeevat, Simon van der Pol, Tjalke Westra, et al.
Expert Review of Vaccines
|
August 2, 2019
Health economic evaluation of current vaccination strategies and new vaccines against tuberculosis: a systematic review
Afifah Machlaurin, Simon van der Pol, Didik Setiawan, et al.
Page
of 3
Search research articles
Search
Showing results (1-10 of 29) with videos related to
Sort By:
Page
of 3
The European Journal of Health Economics : HEPAC : Health Economics in Prevention and Care
|
March 14, 2024
Antivirals to prepare for surges in influenza cases: an economic evaluation of baloxavir marboxil for the Netherlands
Simon van der Pol, Maarten J Postma, Cornelis Boersma
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research
|
March 16, 2017
An Economic Evaluation of Sacubitril/Valsartan for Heart Failure Patients in the Netherlands
Simon van der Pol, Fabian Degener, Maarten J Postma, et al.
Vaccine
|
April 17, 2024
Cost-effectiveness of high-dose influenza vaccination in the Netherlands: Incorporating the impact on both respiratory and cardiovascular hospitalizations
Simon van der Pol, Florian Zeevat, Maarten J Postma, et al.
Bulletin of the World Health Organization
|
June 27, 2024
Performance assessment to improve public health systems
Jochen O Mierau, Simon van der Pol, Amrit Sandhu, et al.
Vaccines
|
April 27, 2026
Potential Public Health and Economic Impact of the Next-Generation COVID-19 Vaccine mRNA-1283 in The Netherlands
Simon van der Pol, Ekkehard Beck, Tjalke Westra, et al.
BMC Health Services Research
|
March 14, 2020
School health in Europe: a review of workforce expenditure across five countries
Simon van der Pol, Maarten J Postma, Danielle E M C Jansen
Antimicrobial Stewardship & Healthcare Epidemiology : ASHE
|
January 30, 2023
Costs of two vancomycin-resistant enterococci outbreaks in an academic hospital
Simon van der Pol, Mariëtte Lokate, Maarten J Postma, et al.
Pharmacoeconomics
|
February 20, 2025
Cost-Effectiveness Analysis of Nirsevimab for Preventing Respiratory Syncytial Virus-Related Lower Respiratory Tract Disease in Dutch Infants: An Analysis Including All-Infant Protection
Florian Zeevat, Simon van der Pol, Alexia Kieffer, et al.
Advances in Therapy
|
February 10, 2025
Cost-effectiveness Analysis of COVID-19 mRNA XBB.1.5 Fall 2023 Vaccination in the Netherlands
Florian Zeevat, Simon van der Pol, Tjalke Westra, et al.
Expert Review of Vaccines
|
August 2, 2019
Health economic evaluation of current vaccination strategies and new vaccines against tuberculosis: a systematic review
Afifah Machlaurin, Simon van der Pol, Didik Setiawan, et al.
Page
of 3